Spirulina in covid 19

Phase 3

• Conditions: Covid19,Virus identified.; COVID19 , Virus identified; U07.1

• Registration Number: IRCT20101201005287N4
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

confirmation of Covid19 by PCR test
satisfaction to participate in the study

Exclusion Criteria

Having an underlying disease
peregnancy
stop taking the drug

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interleukin-6 blood levels of patients before and after taking the drug. Timepoint: Before starting the drug and 14 days after taking the drug. Method of measurement: Blood sample analysisfor IL-6 by ELIZA in the labratory.

Secondary Outcome Measures

Name	Time	Method
Serum TNF-a levels in patients plasma. Timepoint: Before starting the drug and 14 days after starting the drug. Method of measurement: Blood sample analysis for TNF-a by ELIZA in the laboratory.